China NMPA Drug Inspection - Yunnan Zongshun Biotechnology Co., Ltd. - Small pith

The Yunnan Provincial Drug Administration issued its second 2018 announcement on November 30, 2018, detailing 97 batches of non-compliant drugs identified during province-wide supervision and sampling inspections. These inspections targeted drug production, distribution, and use units to ensure public medication safety. Several pharmaceutical manufacturers were cited for quality failures, prominently including Yunnan Jinfeng Pharmaceutical Co., Ltd., Yunnan Suimin Biotechnology Development Co., Ltd., Yunnan Zongshun Biotechnology Co., Ltd., Kunming Daodi Traditional Chinese Medicine Slices Factory, and Yunnan Ningkun Biotechnology Co., Ltd. The primary violations involved various quality control deficiencies, such as issues with "Properties," "Appearance," general "Inspection" parameters, "Identification," and "Extractives." Other specific problems noted were "Quantity Difference," "Dissolution Time," and "Content Determination." All drugs were assessed against the standards outlined in the Chinese Pharmacopoeia, predominantly the 2015 edition, with some references to earlier editions or specific general rules for medicinal materials. While the announcement primarily serves to inform the public and strengthen drug quality oversight, it implicitly mandates that the identified manufacturers address these significant deviations from established pharmacopoeial standards to prevent future non-compliance and safeguard consumer health.